<DOC>
	<DOC>NCT00467012</DOC>
	<brief_summary>To investigate the efficacy, safety, and pharmacokinetics when R435 and paclitaxel are administered concomitantly to patients with metastatic breast cancer.</brief_summary>
	<brief_title>Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>At least 20 years old and obtained a written informed consent Advanced breast cancer (StageⅣ) or Inoperable metastatic breast cancer HER2 negative At least one measurable lesion based on RECIST criteria No previous chemotherapy for metastatic breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Inoperable metastatic breast cancer</keyword>
</DOC>